News
FUSN
21.40
0.00%
0.00
AstraZeneca, Through A Subsidiary, Will Acquire All Of Fusion's Outstanding Shares For A Price Of $21.00 Per Share In Cash At Closing Plus A Non-Transferable CVR Representing The Contingent Right To Receive $3.00/Share In Cash Payable Upon The Achievement Of A Specified Regulatory Milestone, Pursuant And Subject To The Terms And Conditions Of A Contingent Value Rights Agreement
Fusion Pharmaceuticals Inc. Is a clinical-stage oncology company focused on developing next-generation radioconjucates as precision medicines. AstraZeneca plc will acquire all of Fusion's outstanding shares in a previously announced arrangement. The Arrangement is subject to approval by Fusion's shareholders.
Benzinga · 8h ago
*Fusion Pharmaceuticals: AstraZeneca to Acquire All of Fusion's Shrs at $21 Each in Cash >FUSN
Dow Jones · 8h ago
*Fusion Pharmaceuticals: Ontario Superior Court of Justice Issues Interim Order Regarding AstraZeneca Deal >FUSN
Dow Jones · 8h ago
*Fusion Pharmaceuticals: Court Authorizes Special Hldr Meeting, Mailing of Circular >FUSN
Dow Jones · 8h ago
FUSION PHARMACEUTICALS MAILS CIRCULAR FOR SPECIAL MEETING OF SHAREHOLDERS AND ANNOUNCES RECEIPT OF INTERIM ORDER
Reuters · 8h ago
Press Release: Fusion Pharmaceuticals Mails -2-
This communication has been prepared in respect of the transaction involving Fusion, AstraZeneca AB and 15863210 Canada Inc. Fusion has filed the Circular with the SEC and CSA in connection with the transaction. The Circular is in the process of being mailed to Shareholders.
Dow Jones · 8h ago
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
NASDAQ · 2d ago
Weekly Report: what happened at FUSN last week (0415-0419)?
Weekly Report · 3d ago
Fusion Pharmaceuticals Cut to Hold From Buy by TD Cowen
Dow Jones · 04/16 12:03
TD Cowen Downgrades Fusion Pharmaceuticals to Hold
Benzinga · 04/16 11:52
FUSION PHARMACEUTICALS INC <FUSN.O>: TD COWEN CUTS TO HOLD FROM BUY
Reuters · 04/16 05:53
Weekly Report: what happened at FUSN last week (0408-0412)?
Weekly Report · 04/15 09:25
Fusion Pharmaceuticals: Market Perform Rating Amid Acquisition and Promising Prostate Cancer Treatment Data
TipRanks · 04/12 05:37
Fusion Pharmaceuticals Inc. (FUSN) Flat As Market Gains: What You Should Know
NASDAQ · 04/11 21:50
AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO's Pay Package Boost
AstraZeneca Plc raised its annualized dividend for 2024 by $0.20 to $3.10 per share. The company said the 7% increase takes into account other capital allocation priorities. AstraZeneca said the increase reflects its confidence in its performance and cash generation.
Benzinga · 04/11 13:04
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and Fusion Pharmaceuticals (FUSN)
TipRanks · 04/10 11:30
FUSION PHARMACEUTICALS INC - FPI-2265 PHASE 3 GLOBAL REGISTRATIONAL TRIAL IS EXPECTED TO BEGIN IN 2025
Reuters · 04/09 20:05
FUSION PHARMACEUTICALS INC - FPI-2265 PHASE 2 PORTION IS EXPECTED TO BE INITIATED IN Q2 OF 2024
Reuters · 04/09 20:05
Weekly Report: what happened at FUSN last week (0401-0405)?
Weekly Report · 04/08 09:27
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race
AstraZeneca Plc’s Chief Executive Pascal Soriot says the company reached a sales target of $45 billion by 2023. The goal was set a decade ago amid pressure from U.S. Rival Pfizer Inc. AstraZeneca faces the challenge of convincing investors that its best days are not behind it.
Benzinga · 04/02 18:54
More
Webull provides a variety of real-time FUSN stock news. You can receive the latest news about Fusion Pharmaceuticals Inc. through multiple platforms. This information may help you make smarter investment decisions.
About FUSN
Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. It has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by its ability to radiolabel various classes of targeting molecules, its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals, its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging agents. Its clinical portfolio includes FPI-2265, FPI-1434 and FPI-2059. FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer in a Phase 2 trial.